Skip to content

The Cancer Letter – Friends of Cancer Research launches Step 2 of the ctMoniTR Project

The Cancer Letter – Friends of Cancer Research launches Step 2 of the ctMoniTR Project

Friends of Cancer Research has launched Step 2 of the ctDNA for Monitoring Treatment Response (ctMoniTR) Project.

This project aims to determine the extent to which changes in circulating tumor DNA (ctDNA) are an early indicator of response to therapy on a larger scale than has been done before.

With the launch of Step 2, Friends and its project partners will collect data on the use of ctDNA to monitor treatment response in more than 25 studies representing over 3,000 cancer patients, 16 additional treatments, and several cancer types.

The group anticipates releasing preliminary Step 2 data in 2022. Full results from Step 1, which show that early changes in ctDNA following PD1/PDL1 treatment in advanced lung cancer were a strong indicator of long-term outcomes across multiple clinical trials, are forthcoming with a publication release date to be announced at a later time.

The data that will be compiled in Step 2 will supply evidence needed to determine whether ctDNA can identify patients responding to therapy or not at an earlier time point than available methods.

“This is an opportunity to validate a new tool which would allow patients and physicians to know sooner and more accurately if treatments are working,” Jeff Allen, president and CEO of Friends of Cancer Research, said in a statement.

The goal of Step 2 of ctMoniTR is to expand the study of the relationship between ctDNA and clinical outcomes across a number of clinical settings that include several drug classes and tumor types. The use of ctDNA is changing at a rapid pace and the working group aims to evaluate the value of ctDNA in additional cancers and therapies.

Friends of Cancer Research is partnering with 25 organizations on this topic: AstraZeneca, Bayer, Biodesix, Boehringer Ingelheim, Bristol Myers Squibb, Cancer Research And Biostatistics (CRAB), EMD Serono, Inc., US Food and Drug Administration (FDA), Foundation Medicine, Inc., Genentech, Inc., Guardant Health, Inc., Illumina, Inc., Johns Hopkins University, Lilly Oncology, Merck & Co. Inc., Molecular Characterization Laboratory at Frederick National Laboratory, Memorial Sloan Kettering Cancer Center, Natera, Inc., NMD Group LLC., Novartis AG, Pfizer, Inc., Princess Margaret Cancer Centre, Regeneron Pharmaceuticals Inc., Resolution Bioscience, Inc., Takeda Pharmaceutical Company.